Drug intelligence / Profile preview

CATB-102

Development stage: Preclinical
Lead developer: Catena Biosciences
Modality: Antibody-Based Therapeutics

Overview

CATB-102 is an investigational antibody drug developed by Catena Biosciences. It is currently in preclinical development for the treatment of solid tumors, falling under the therapeutic area of neoplasms. The specific mechanism of action and molecular target have not been publicly disclosed as of the latest available information[1].

Brand names: CATB-102CATB102CATB 102
Other names: CATB-102CATB102CATB 102

Beyond the preview

Go deeper on CATB-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CATB-102.

Explore the full profile